Published in Eur J Clin Pharmacol on January 01, 1977
Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol (1982) 1.51
Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem Res Toxicol (2011) 1.11
A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients. Br J Clin Pharmacol (1981) 0.91
Sulphinpyrazone metabolism during long-term therapy. Br J Clin Pharmacol (1981) 0.78
Increased oxidation of phenylbutazone during hydrocortisone infusion in man. Br J Clin Pharmacol (1977) 0.75
Pharmaceutical Metabolism in Fish: Using a 3-D Hepatic In Vitro Model to Assess Clearance. PLoS One (2017) 0.75
Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths). Br J Pharmacol (1971) 6.11
Pharmacokinetics of inhaled substances. Postgrad Med J (1975) 3.52
Isoprenaline resistance and the use of pressurised aerosols in asthma. Lancet (1968) 3.33
Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther (1976) 3.13
Assessment of antipyrine kinetics by measurement in saliva. Br J Clin Pharmacol (1976) 2.78
Blood concentrations in man of fluorinated hydrocarbons after inhalation of pressurised aerosols. Lancet (1970) 2.48
The fate of isoprenaline administered by pressurized aerosols. Br J Pharmacol (1970) 2.43
Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. Br J Clin Pharmacol (1978) 2.14
Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin Sci (1971) 2.11
The metabolic fate of DL(7-3H)isoprenaline in man and dog. Biochem J (1969) 2.06
Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline. Lancet (1977) 2.01
Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther (1977) 1.91
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol (1981) 1.81
Mixed function oxidase activity in microsomal fractions of human liver biopsy specimens [proceedings]. Br J Clin Pharmacol (1978) 1.75
Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol (1980) 1.69
Changes in liver blood flow during enzyme induction. Biochem Pharmacol (1971) 1.65
Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos (1974) 1.63
The fate of ethyltin and diethyltin derivatives in the rat. Biochem J (1967) 1.62
Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety. Clin Pharmacol Ther (1984) 1.59
Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther (1997) 1.56
CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res (1994) 1.49
Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol (1981) 1.47
Leucovorin and maximum tolerated dose toxicity of methotrexate in rats. Pediatr Hematol Oncol (2000) 1.41
The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol (1980) 1.40
[Placebo in drug clinical trials]. Med Clin (Barc) (1997) 1.40
Typhoid Carriers, with an account of Two Institution Outbreaks traced to the same "Carrier.". Proc R Soc Med (1908) 1.39
Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol (1990) 1.38
Metabolism of isoprenaline in dog and man. Br J Pharmacol (1972) 1.38
Metabolism of isoprenaline after aerosol and direct intrabronchial administration in man and dog. Br J Pharmacol (1974) 1.32
Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol (1981) 1.32
Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol (1983) 1.29
A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol (1988) 1.28
Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol (1973) 1.28
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol (1986) 1.25
Fluorescence studies on some hydroxypyridines including compounds of the vitamin B6 group. Biochem J (1966) 1.23
Clinical pharmacokinetics of phenylbutazone. Clin Pharmacokinet (1978) 1.21
Pharmacokinetics of metoclopramide. Lancet (1979) 1.20
Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Ann N Y Acad Sci (1971) 1.20
Nucleosomes bind to cell surface proteoglycans. J Biol Chem (1999) 1.20
The fate of inhaled terbutaline. Eur J Respir Dis Suppl (1984) 1.20
Species and sex differences in electron transport systems in liver microsomes and their relationship to ethylmorphine demethylation. Life Sci (1969) 1.20
Concentration effect studies with oral metoclopramide. Br J Clin Pharmacol (1979) 1.18
Mechanisms of cell death. Arch Toxicol (1991) 1.17
Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clin Sci Mol Med (1977) 1.17
Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol (1977) 1.16
Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro. Eur J Clin Pharmacol (1981) 1.12
Metabolism of isoprenaline in the intestine. J Pharm Pharmacol (1974) 1.12
Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension. Br J Clin Pharmacol (1979) 1.09
The conduct of initial drug studies in man. Br Med Bull (1970) 1.08
Hydroxylation of aromatic hydrocarbons in the rat. Toxicol Appl Pharmacol (1970) 1.07
Sex differences in the kinetic constants for the N-demethylation of ethylmorphine by rat liver microsomes. Biochem Pharmacol (1968) 1.07
Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion. Br J Clin Pharmacol (1983) 1.05
The analysis of terbutaline in biological fluids by gas chromatography electron impace mass spectrometry. Biomed Mass Spectrom (1979) 1.03
Differences in the metabolism of drugs depending upon their routes of administration. Ann N Y Acad Sci (1971) 1.03
Demonstration of rheumatoid factor in tissue by mixed agglutination with tissue sections. Arthritis Rheum (1968) 1.03
Antipyrine as an in vitro probe of mixed function oxidase activity [proceeding]. Br J Clin Pharmacol (1980) 1.02
Detection and measurement of MeIQx in human urine after ingestion of a cooked meat meal. Carcinogenesis (1989) 1.02
"First-pass" metabolism of paracetamol in rat liver. J Pharm Pharmacol (1974) 1.02
Individual differences in the plasma half-lives of lipid soluble drugs in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.01
Analysis of simple phenols of interest in metabolism. II. Conjugate hydrolysis and extraction methods. Anal Biochem (1969) 1.01
Kinetics of paraquat elimination in the dog. Toxicol Appl Pharmacol (1981) 1.00
Studies on the degradation of tyrosine by rat caecal contents. Scand J Gastroenterol (1969) 1.00
The absorption and elimination of metoclopramide in three animal species. J Pharm Pharmacol (1976) 1.00
The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol (1989) 1.00
Letter: Clonidine overdose. Br Med J (1975) 0.99
Extra-nuclear location of histones in activated human peripheral blood lymphocytes and cultured T-cells. Biochem Pharmacol (1995) 0.98
Heterocyclic amines: evaluation of their role in diet associated human cancer. Br J Clin Pharmacol (1996) 0.98
Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol (1990) 0.97
Immunological and histological studies of temporal arteries from patients with temporal arteritis and/or polymyalgia rheumatica. Acta Pathol Microbiol Scand A (1976) 0.97
Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit? Lancet (1988) 0.97
Human cytochromes P-450. Xenobiotica (1984) 0.96
Mechanisms of cell death. Trends Pharmacol Sci (1989) 0.96
The metabolism of clonidine and related imidazoline derivatives in rat liver [proceedings]. Br J Pharmacol (1978) 0.96
Apparent resistance to hypotensive effect of clonidine. Br Med J (1977) 0.96
N-acetylcysteine for paracetamol overdose. Lancet (1986) 0.96
Immunocytochemical localization of cytochrome P-450 in hepatic and extra-hepatic tissues of the rat with a monoclonal antibody against cytochrome P-450 c. Biochem Pharmacol (1986) 0.95
The metabolism of sympathomimetic bronchodilator drugs by the isolated perfused dog lung. Xenobiotica (1973) 0.95
Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? Br J Clin Pharmacol (1985) 0.95
Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. AIDS Res Hum Retroviruses (1997) 0.94
Competition for sulphate during detoxification in the gut wall. Nature (1975) 0.94
Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) by human liver microsomes. Carcinogenesis (1994) 0.93
Arthritis in myasthenia gravis. J Neurol Neurosurg Psychiatry (1975) 0.93
Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. Biochem Pharmacol (1985) 0.92
Interindividual variation in kinetics of infused epinephrine. Clin Pharmacol Ther (1979) 0.92
Reversal of acetaminophen toxicity in isolated hamster hepatocytes by dithiothreitol. Toxicol Appl Pharmacol (1986) 0.92
Reduction of circulating 25-hydroxyvitamin D by antipyrine. Br J Clin Pharmacol (1979) 0.92
The influence of the route of administration on urinary metabolites of isoetharine. Xenobiotica (1974) 0.92
The measurement of MeIQx adducts with mouse haemoglobin in vitro and in vivo: implications for human dosimetry. Carcinogenesis (1991) 0.91
Pharmacokinetic and concentration-effect studies with metoclopramide [proceedings]. Br J Clin Pharmacol (1977) 0.91
Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells. Br J Pharmacol (1994) 0.91
Identification and location of alpha-helices in mammalian cytochromes P450. Biochemistry (1989) 0.91
Comparative pharmacokinetics of theophylline and aminophylline in man. Br J Clin Pharmacol (1981) 0.91
Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol (1982) 0.91
Rapid tolerance to the hypotensive effects of glyceryl trinitrate in the rat: prevention by N-acetyl-L- but not N-acetyl-D-cysteine. Br J Pharmacol (1990) 0.91
Plasma concentration of phenylbutazone and its therapeutic effect-studies in patients with rheumatoid arthritis. Br J Clin Pharmacol (1976) 0.90
Changes in lipid metabolizing enzymes of hepatic subcellular fractions from rats treated with tiadenol and clofibrate. Biochem Pharmacol (1981) 0.90
Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol (1998) 0.90